Lead Product(s): Undisclosed
Therapeutic Area: Oncology
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: $507.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration January 09, 2020
This license and collaboration agreement is to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K pathways.